Abstract
To gain better understanding of the molecular alterations responsible for the aggressive growth potential of epidermal growth factor receptor (EGFR)-positive breast cancers, we utilized an expression cloning strategy to seek gene products that mediate the EGF-independent growth of human breast cancer cells. A retroviral cDNA expression library was constructed from the EGFR-positive SUM-149PT cell line, and transduced into growth factor-dependent human mammary epithelial (HME) cells. Recipient cells were functionally selected for their ability to proliferate in serum-free, EGF-free medium. Library cDNAs were recovered from EGF-independent colonies by PCR amplification or by biological rescue. Clone H55a#1 contained a library insert encoding amphiregulin. This EGFR ligand was able to confer EGF independence when transduced into HME cells. SUM-149PT and H55a#1 cells overexpressed amphiregulin transcripts, and secreted moderate EGF-like activity in conditioned media, indicating a possible autocrine loop. EGFR membrane levels and constitutive phosphorylation were consistent with this hypothesis, as well as the sensitivity of the cells to an ErbB-specific kinase inhibitor. Expression of the WT1 Wilms' tumor suppressor gene, a transcriptional activator of amphiregulin, did not parallel amphiregulin transcript levels, suggesting that another factor regulates amphiregulin in SUM-149PT. Our data confirm the importance of amphiregulin in the etiology of breast cancer.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Band V, Sager R . 1989 Proc. Natl. Acad. Sci. USA 86: 1249–1253
Band V, Zajchowski D, Swisshelm D, Trask D, Kulesa V, Cohen C, Connolly J, Sager R . 1990 Cancer Res. 50: 7351–7357
Barnard JA, Graves-Deal R, Pittelkow MR, DuBois R, Cook P, Ramsey GW, Bishop PR, Damstrup L, Coffey RJ . 1994 J. Biol. Chem. 269: 22817–22822
Battaglia F, Scambia G, Rossi S, Panici PB, Bellantone R, Polizzi G, Querzoli P, Negrini R, Iacobelli S, Crucitti F, Mancuso S . 1988 Eur. J. Cancer Clin. Oncol. 24: 1685–1690
Brown P, Fuqua S, Allred C . 2000 Endocrine Oncology: Contemporary Endocrinology. Ethier SP. (ed) Humana Press: Totowa, NJ pp. 49–68
Clarke RB, Howell A, Potten CS, Anderson E . 1997 Cancer Res. 57: 4987–4991
Ekstrand AJ, Longo N, Hamid ML, Olson JJ, Collins VP, James CD, Liu L . 1994 Oncogene 9: 2313–2320
Ethier SP . 1995 J. Natl. Cancer Inst. 87: 964–973
Ethier SP, Chiodino C, Jones RF . 1990a Cancer Res. 50: 5351–5357
Ethier SP, Kudla A, Cundiff KC . 1987 J. Cell. Physiol. 132: 161–167
Ethier SP, Langton BC, Dilts CA . 1996 Mol. Carcinog. 15: 134–143
Ethier SP, Moorthy R, Dilts CA . 1991 Cell Growth Diff. 2: 593–602
Ethier SP, Summerfelt RM, Cundiff KC, Asch BB . 1990b Breast Cancer Res. Treat. 17: 221–230
Forozan F, Veldman R, Ammerman, CA, Parsa NZ, Kallioniemi A, Kallioniemi OP, Ethier SP . 1999 Br. J. Cancer 81: 1328–1334
Fry DW, Bridges AJ, Denny WA, Doherty A, Greis KD, Hicks JL, Hook KE, Keller PR, Leopold WR, Loo JA, McNamara DJ, Nelson JM, Sherwood V, Smaill JB, Trumpp-Kallmeyer S, Dobrusin EM . 1998 Proc. Natl. Acad. Sci. USA 95: 12022–12027
Fry DW, Kraker AJ, McMichael A, Ambroso LA, Nelson JM, Leopold WR, Connors RW, Bridges AJ . 1994 Science 265: 1093–1095
Harris AL, Nicholson S, Sainsbury JRC, Farndon J, Wright C . 1989 J. Steroid Biochem. 34: 123–131
Hitoshi Y, Lorens J, Kitada SI, Fisher J, LaBarge M, Ring HZ, Francke U, Reed JC, Kinoshita S, Nolan GP . 1998 Immunity 8: 461–471
Holdaway IM, Bowditch JV . 1983 Cancer 52: 479–485
Johnson GR, Kannan B, Shoyab M, Stromberg K . 1993 J. Biol. Chem. 268: 2924–2931
Kenney NJ, Smith GH, Rosenberg K, Cutler ML, Dickson RB . 1996 Cell Growth Diff. 7: 1769–1781
Kinoshita S, Su L, Amano M, Timmerman LA, Kaneshima H, Nolan GP . 1997 Immunity 6: 235–244
Kitamura T, Onishi M, Kinoshita S, Shibuya A, Miyajima A, Nolan GP . 1995 Proc. Natl. Acad. Sci. USA 92: 9146–9150
Kuukasjarvi T, Kononen J, Helin H, Holli K, Isola J . 1996 J. Clin. Oncol. 14: 2584–2589
Lee SB, Huang K, Palmer R, Truong VB, Herzlinger D, Kolquist KA, Wong J, Paulding C, Yoon SK, Gerald W, Oliner JD, Haber DA . 1999 Cell 98: 663–673
LeJeune S, Leek R, Horak E, Plowman G, Greenall M, Harris AL . 1993 Cancer Res. 53: 3597–3602
Ma L, Gauville C, Berthois Y, Millot G, Johnson GR, Calvo F . 1999 Oncogene 18: 6513–6520
MartÃnez-Lacaci I, Saceda M, Plowman GD, Johnson GR, Normanno N, Salomon DS, Dickson RB . 1995 Endocrinology 136: 3983–3992
Nicholson S, Halcrow P, Farndon JR, Sainsbury JRC, Chambers P, Harris AL . 1989 Lancet 8631: 182–185
Nicholson S, Wright C, Sainsbury JR, Halcrow P, Kelly P, Angus B, Farndon JR, Harris AL . 1990 J. Steroid Biochem. Mol. Biol. 37: 811–814
Nicholson S, Sainsbury JRC, Needham GK, Chambers P, Farndon JR, Harris AL . 1988 Intl. J. Cancer 42: 36–41
Nishikawa R, Ji XD, Harmon RC, Lazar CS, Gill GN, Cavenee WK, Huang HJS . 1994 Proc. Natl. Acad. Sci. USA 91: 7727–7731
Normanno N, Kim N, Wen D, Smith K, Harris AL, Plowman G, Colletta G, Ciardiello F, Salomon DS . 1995 Breast Cancer Res. Treat. 35: 293–297
Osborne CK . 1985 Semin. Oncol. 12: 317–326
Pear WS, Nolan GP, Scott ML, Baltimore D . 1993 Proc. Natl. Acad. Sci. USA 90: 8392–8396
Pfeiffer JK, Topping RS, Shin NH, Telesnitsky A . 1999 J. Virol. 73: 8441–8447
Plowman GD, Green JM, McDonald VL, Neubauer MG, Disteche CM, Todaro GJ, Shoyab M . 1990 Mol. Cell. Biol. 10: 1969–1981
Qi CF, Liscia DS, Normanno N, Merlo G, Johnson GR, Gullick WJ, Ciardiello F, Saeki T, Brandt R, Kim N, Kenney N, Salomon DS . 1994 Br. J. Cancer 69: 903–910
Ram TG, Ethier SP . 1996 Cell Growth Differ. 7: 551–561
Ram TG, Kokeny KE, Dilts CA, Ethier SP . 1995 J. Cell. Physiol. 163: 589–596
Rao GS, Murray S, Ethier SP . 2000 Intl. J. Radiation Oncol. Biol. Phys. 48: 1519–1528
Salomon DS, Bianco C, De Santis M, MartÃnez-Lacaci I, Wechselberger C, Ebert AD . 2000 Endocrine Oncology: Contemporary Endocrinology. Ethier SP. (ed. Humana Press: Totowa, NJ pp. 137–191
Schlegel J, Merdes A, Stumm G, Albert FK, Forsting M, Hynes N, Kiessling M . 1994 Intl. J. Cancer 56: 72–77
Silberstein GB, Van Horn K, Strickland P, Roberts Jr CT, Daniel CW . 1997 Proc. Natl. Acad. Sci. USA 94: 8132–8137
Smaill JB, Rewcastle GW, Loo JA, Greis JD, Chan OH, Reyner EL, Lipka E, Showalter HDH, Fry DW, Sherwood V, Nelson JM, Denny WA . 2000 J. Med. Chem. 43: 1380–1397
Soule HD, Malony TM, Wolman SR, Peterson WD, Brenz R, McGrath CM, Russo J, Pauley RJ, Jones RF, Brooks SC . 1990 Cancer Res. 50: 6075–6086
Tannheimer SL, Rehemtulla A, Ethier SP . 2000 Breast Cancer Res. 2: 311–320
Toi M, Hamada Y, Nakamura T, Mukaida H, Suehiro S, Wada T, Toge T, Nimoto M, Hattori T . 1989 Intl. J. Cancer 43: 220–225
Visscher DW, Sarkar FH, Kasunic TC, Reddy KB . 1997 Breast Cancer Res. Treat. 45: 75–80
Whitehead I, Kirk H, Kay R . 1995 Mol. Cell. Biol. 15: 704–710
Woods Ignatoski KM, Ethier SP . 1999 Breast Cancer Res. Treat. 54: 173–182
Woods Ignatoski KM, Lapointe AJ, Radany EH, Ethier SP . 1999 Endocrinology 140: 3615–3622
zur Hausen H . 1999 Semin. Cancer Biol. 9: 405–411
Acknowledgements
We thank Dr Alice Telesnitsky for the pMLV Ψ-plasmid, Drs Stephan Stoll and JT Elder for the amphiregulin probe fragment, and Drs Wilber Leopold and David Fry for the CI-1033 EGFR kinase inhibitor. We also express our appreciation to Drs Michael Imperiale, Eric Fearon and the members of the Ethier laboratory for helpful discussions and Mrs Amy Pace for preparing the figures. This work was supported in part by Grant RO1 CA77416 from the NIH (to SP Ethier) and by a postdoctoral fellowship from the Pardee Foundation (to IM Berquin).
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Berquin, I., Dziubinski, M., Nolan, G. et al. A functional screen for genes inducing epidermal growth factor autonomy of human mammary epithelial cells confirms the role of amphiregulin. Oncogene 20, 4019–4028 (2001). https://doi.org/10.1038/sj.onc.1204537
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.onc.1204537
Keywords
This article is cited by
-
Amphiregulin deletion strongly attenuates the development of estrogen receptor-positive tumors in p53 mutant mice
Breast Cancer Research and Treatment (2020)
-
Riluzole synergizes with paclitaxel to inhibit cell growth and induce apoptosis in triple-negative breast cancer
Breast Cancer Research and Treatment (2017)
-
Self-reinforcing loop of amphiregulin and Y-box binding protein-1 contributes to poor outcomes in ovarian cancer
Oncogene (2014)
-
YAP-dependent induction of amphiregulin identifies a non-cell-autonomous component of the Hippo pathway
Nature Cell Biology (2009)
-
Amphiregulin: Role in Mammary Gland Development and Breast Cancer
Journal of Mammary Gland Biology and Neoplasia (2008)